UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ) , reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available... Read More

UPPSALA, Sweden, April 02, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases. In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over... Read More

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basis Full year revenue 2023 revenue totaled $169.6... Read More

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/ . About Olink Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the... Read More

UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company’s facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30 p.m. CET. NOTICE OF PARTICIPATION Shareholders who wish to... Read More

UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19 th , 2024. The AGM was previously scheduled to take place on April 17 th , 2024. About Olink Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific... Read More

UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023. Highlights Third quarter 2023 revenue totaled $44.2 million, representing year over year growth of 39% on a reported basis and 38% on a constant currency adjusted like-for-like basis Total Explore customer installations reached 87,... Read More

UPPSALA, Sweden, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that Novogene Asia Pacific Middle East and Africa (AMEA) has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region. Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing... Read More

UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three articles in the prestigious scientific journal, Nature , that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13... Read More

UPPSALA, Sweden, September 19, 2023 (GLOBE NEWSWIRE) – Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink® Target 48 Mouse Cytokine Panel, a validated multiplexed protein panel that offers a detailed view of the murine immune system, enabling in-depth disease modelling, longitudinal studies and translational research. The Olink Target 48 Mouse Cytokine Panel represents a new standard in... Read More

UPPSALA, Sweden, 12 th September, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology. The Olink platform represents the cutting edge in proteomics technology, delivering exceptional sensitivity and... Read More

UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: Goldman Sachs 20 th Annual European Medtech and Healthcare Services Conference Thursday, September 7 th at 7:15 am ET Morgan Stanley 21 st Annual Global Healthcare Conference Tuesday, September 12 th at 1:35 pm ET A live and archived... Read More

UPPSALA, Sweden, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the second quarter ended June 30, 2023. Highlights Second quarter 2023 revenue totaled $29.4 million, representing year over year growth of 7.0% on a reported basis and 7.2% on a constant currency adjusted like-for-like basis Total Explore customer installations reached 74,... Read More

UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering. Understanding the complex biological mechanisms of human diseases is essential to identifying effective new therapeutic... Read More

UPPSALA, Sweden, July 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will host a conference call to discuss these results at 8:00 am ET. Investors interested in listening to the conference call are required to register online . It is recommended... Read More

UPPSALA, Sweden, July 12, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink ® Explore HT, a transformational solution for high-throughput proteomics delivering unmatched specificity, scalability, and workflow simplicity. Olink Explore HT represents a significant... Read More

UPPSALA, Sweden, June 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of new findings into the variability of the human proteome, based on measurements of approximately 1,500 proteins in over 50,000 participants from the UK Biobank (UKB). The findings will be shared through... Read More

UPPSALA, Sweden, May 25, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: William Blair 43 rd Annual Growth Stock Conference Tuesday, June 6 th Goldman Sachs 44 th Annual Global Healthcare Conference Wednesday, June 14 th at 2:00 pm PT / 5:00 pm ET A live and archived webcast of the Goldman Sachs Global... Read More

UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023. Highlights First quarter 2023 revenue totaled $27.5 million, representing year over year growth of 21% on a reported basis and 25% on a constant currency adjusted like-for-like basis Total Explore customer installations reached 63, with... Read More

UPPSALA, Sweden, April 17, 2023 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ) , reg. no 559189-7755, (the “Company”), on 17 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available... Read More

UPPSALA, Sweden, April 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2023 before the market open on Thursday, May 11, 2023. Company management will host a conference call to discuss these results at 8:00 am ET. Investors interested in listening to the conference call are required to register online . It is recommended to... Read More

UPPSALA, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic facility, D-CYPHR in Cape Town, South Africa has adopted Olink technology and has become the first service provider using the Olink ® Target and Olink ® Flex platforms for targeted protein biomarker discovery on the African continent. D-CYPHR is a new facility co-founded by the Centre for... Read More

UPPSALA, Sweden, March 27, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2022 is now available on the Company’s website at https://investors.olink.com/ . About Olink Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and... Read More

UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company’s global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. “I am... Read More

UPPSALA, Sweden, March 15, 2023 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Monday the 17 April 2023, in the Company’s facilities at Salagatan 18B, Uppsala. Registration for the meeting commences at 3:30 p.m. CET. NOTICE OF PARTICIPATION Shareholders who wish to... Read More

UPPSALA, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink ® Explore 3072, Olink ® Explore 1536, Olink ® Target 96 and Target 48, and the recently launched Olink ® Flex platforms. These... Read More

UPPSALA, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of Olink High-Plex offerings as a proteomics platform of choice, with a goal of generating proteomic data at scale to augment RGC’s vast genomics information store. RGC is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that... Read More

UPPSALA, Sweden, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2022. Highlights Fourth quarter revenue totaled $57.9 million, representing year over year growth of 33% on a reported basis and 37% on a constant currency adjusted like-for-like basis Full year 2022 revenue totaled $139.8... Read More

Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ADSs”), consisting of 4,250,000 ADSs offered by the Company and 1,581,028 ADSs offered by certain selling shareholders of the Company (the “Selling Shareholders”),... Read More

Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“ Olink ” or the “ Company ”), today announced the launch of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ ADSs ”), consisting of 4,250,000 ADSs offered by the Company and 1,581,028 ADSs offered by certain selling shareholders of the Company (the “ Selling... Read More

UPPSALA, Sweden, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink” or the “Company”) (Nasdaq: OLK), today announced preliminary unaudited revenue for the fourth quarter and year ended December 31, 2022, and additional selected unaudited performance metrics. Full year 2022 reported revenues are expected to be between $139.4 million and $139.8 million, representing yearly growth of approximately 47% on a... Read More

UPPSALA, Sweden, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 41 st Annual JP Morgan Healthcare Conference. Company management will present on Wednesday, January 11 th , 2023 at 7:30 am PT. A live and archived webcast of the event will be available on the “Events” section of the Company’s website at https://investors.olink.com/news-events/events.... Read More

Creates a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis to support drug and diagnostic development HUNTSVILLE, Ala. , Dec. 14, 2022 /CNW/ -- Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research... Read More